GSK plc filed a Form 6-K on November 12, 2026, disclosing Share Reward Plan acquisitions of ordinary shares and American Depositary Shares by nine persons discharging managerial responsibilities (PDMRs) or their closely associated persons, with transactions dated November 9 and November 10, 2026.

Key Highlights

  • Eight participants acquired ordinary shares: Lynn Baxter, Julie Brown, David Redfern, Regis Simard, James Strenner, Philip Thomson, Neil Falkingham, and Victoria Whyte each acquired GSK ordinary shares of 31 1/4 pence each (ISIN: GB00BN7SWP63) on November 10, 2026, on the London Stock Exchange.
  • Price for ordinary share transactions: All ordinary share acquisitions were executed at £19.3453 per share, according to the filing.
  • Most participants received 12 shares: Seven of the eight ordinary share participants each acquired 12 shares (6 partnership shares and 6 matching shares); Victoria Whyte acquired 14 shares (7 partnership shares and 7 matching shares).
  • ADS acquisition by Maya Martinez-Davis: Maya Martinez-Davis, President, US, acquired 9.264 notional American Depositary Shares (ISIN: US37733W2044) within her GSK Executive Supplemental Savings Plan account on November 9, 2026, at $51.5400 per ADS, on the New York Stock Exchange.
  • Neil Falkingham disclosed as a closely associated person: Falkingham is identified in the filing as a person closely associated with Lynn Baxter, CEO, ViiV Healthcare and President, Global Health, GSK.
  • All notifications are initial: Every transaction in the filing is designated as an initial notification, not an amendment.

GSK Discloses November 2026 Share Reward Plan Acquisitions Across Nine PDMRs and Associated Persons

According to the Form 6-K filed with the U.S. Securities and Exchange Commission for the month of November 2026, GSK plc (LEI: 5493000HZTVUYLO1D793) reported Share Reward Plan acquisitions by multiple persons discharging managerial responsibilities. The filing covers transactions executed on November 9 and November 10, 2026, across two types of instruments: ordinary shares traded on the London Stock Exchange and American Depositary Shares traded on the New York Stock Exchange.

For the ordinary share transactions, the filing identifies seven PDMRs - Lynn Baxter (CEO, ViiV Healthcare and President, Global Health, GSK), Julie Brown (Chief Financial Officer), David Redfern (President, Corporate Development), Regis Simard (President, Global Supply Chain), James Strenner (President, Europe), Philip Thomson (President, Global Affairs), and Victoria Whyte (SVP and Company Secretary) - as well as Neil Falkingham, identified as a person closely associated with Lynn Baxter. Each acquisition was described as an "Acquisition of Ordinary Shares under the Company's Share Reward Plan" at a price of £19.3453 per ordinary share. Six of the eight received 12 shares in aggregate (6 partnership shares and 6 matching shares); Victoria Whyte received 14 shares in aggregate (7 partnership shares and 7 matching shares).

Separately, Maya Martinez-Davis, President, US, acquired 9.264 notional ADS units within her GSK Executive Supplemental Savings Plan account on November 9, 2026, at $51.5400 per ADS, according to the filing. The filing describes this as an "Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account" and notes it as a single transaction with no aggregated volume breakdown provided.

What Was Disclosed

GSK plc's Form 6-K reported Share Reward Plan acquisitions by eight ordinary share participants at £19.3453 on November 10, 2026, and one ADS acquisition by Maya Martinez-Davis at $51.5400 on November 9, 2026, all as initial notifications.